Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SCT510A in Wet Age-related Macular Degeneration
NCT04564937Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of SCT510A in exudative macular degeneration (4 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Dose-Limiting Toxicity at Day 14 and Maximum Tolerated Dose at Day 140. Status: unknown.
02
Drugs
SCT510A
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04564937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564937.